Subhash Chauhan to Pancreatic Neoplasms
This is a "connection" page, showing publications Subhash Chauhan has written about Pancreatic Neoplasms.
Connection Strength
7.424
-
Dhasmana A, Dhasmana S, Kotnala S, Laskar P, Khan S, Haque S, Jaggi M, Yallapu MM, Chauhan SC. CEACAM7 expression contributes to early events of pancreatic cancer. J Adv Res. 2024 01; 55:61-72.
Score: 0.651
-
Chaib M, Hafeez BB, Mandil H, Daria D, Pingili AK, Kumari S, Sikander M, Kashyap VK, Chen GY, Anning E, Tripathi MK, Khan S, Behrman S, Yallapu MM, Jaggi M, Makowski L, Chauhan SC. Reprogramming of pancreatic adenocarcinoma immunosurveillance by a microbial probiotic siderophore. Commun Biol. 2022 11 04; 5(1):1181.
Score: 0.638
-
Massey AE, Doxtater KA, Yallapu MM, Chauhan SC. Biophysical changes caused by altered MUC13 expression in pancreatic cancer cells. Micron. 2020 03; 130:102822.
Score: 0.524
-
Massey AE, Sikander M, Chauhan N, Kumari S, Setua S, Shetty AB, Mandil H, Kashyap VK, Khan S, Jaggi M, Yallapu MM, Hafeez BB, Chauhan SC. Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment. Nanomedicine. 2019 08; 20:102027.
Score: 0.503
-
Khan S, Setua S, Kumari S, Dan N, Massey A, Hafeez BB, Yallapu MM, Stiles ZE, Alabkaa A, Yue J, Ganju A, Behrman S, Jaggi M, Chauhan SC. Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer. Biomaterials. 2019 07; 208:83-97.
Score: 0.498
-
Kashyap VK, Wang Q, Setua S, Nagesh PKB, Chauhan N, Kumari S, Chowdhury P, Miller DD, Yallapu MM, Li W, Jaggi M, Hafeez BB, Chauhan SC. Therapeutic efficacy of a novel ?III/?IV-tubulin inhibitor (VERU-111) in pancreatic cancer. J Exp Clin Cancer Res. 2019 Jan 23; 38(1):29.
Score: 0.491
-
Stiles ZE, Khan S, Patton KT, Jaggi M, Behrman SW, Chauhan SC. Transmembrane mucin MUC13 distinguishes intraductal papillary mucinous neoplasms from non-mucinous cysts and is associated with high-risk lesions. HPB (Oxford). 2019 01; 21(1):87-95.
Score: 0.476
-
Khan S, Zafar N, Khan SS, Setua S, Behrman SW, Stiles ZE, Yallapu MM, Sahay P, Ghimire H, Ise T, Nagata S, Wang L, Wan JY, Pradhan P, Jaggi M, Chauhan SC. Clinical significance of MUC13 in pancreatic ductal adenocarcinoma. HPB (Oxford). 2018 06; 20(6):563-572.
Score: 0.457
-
Setua S, Khan S, Yallapu MM, Behrman SW, Sikander M, Khan SS, Jaggi M, Chauhan SC. Restitution of Tumor Suppressor MicroRNA-145 Using Magnetic Nanoformulation for Pancreatic Cancer Therapy. J Gastrointest Surg. 2017 01; 21(1):94-105.
Score: 0.414
-
Khan S, Ebeling MC, Chauhan N, Thompson PA, Gara RK, Ganju A, Yallapu MM, Behrman SW, Zhao H, Zafar N, Singh MM, Jaggi M, Chauhan SC. Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer. Cancer Res. 2015 Jun 01; 75(11):2292-304.
Score: 0.377
-
Khan S, Chauhan N, Yallapu MM, Ebeling MC, Balakrishna S, Ellis RT, Thompson PA, Balabathula P, Behrman SW, Zafar N, Singh MM, Halaweish FT, Jaggi M, Chauhan SC. Nanoparticle formulation of ormeloxifene for pancreatic cancer. Biomaterials. 2015; 53:731-43.
Score: 0.376
-
Khan S, Ebeling MC, Zaman MS, Sikander M, Yallapu MM, Chauhan N, Yacoubian AM, Behrman SW, Zafar N, Kumar D, Thompson PA, Jaggi M, Chauhan SC. MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer. Oncotarget. 2014 Sep 15; 5(17):7599-609.
Score: 0.363
-
Khan S, Kumar D, Jaggi M, Chauhan SC. Targeting microRNAs in pancreatic cancer: microplayers in the big game. Cancer Res. 2013 Nov 15; 73(22):6541-7.
Score: 0.342
-
Yallapu MM, Ebeling MC, Khan S, Sundram V, Chauhan N, Gupta BK, Puumala SE, Jaggi M, Chauhan SC. Novel curcumin-loaded magnetic nanoparticles for pancreatic cancer treatment. Mol Cancer Ther. 2013 Aug; 12(8):1471-80.
Score: 0.331
-
Chauhan SC, Ebeling MC, Maher DM, Koch MD, Watanabe A, Aburatani H, Lio Y, Jaggi M. MUC13 mucin augments pancreatic tumorigenesis. Mol Cancer Ther. 2012 Jan; 11(1):24-33.
Score: 0.297
-
Afaq F, Agarwal S, Bajpai P, Diffalha SA, Kim HG, Peter S, Khushman M, Chauhan SC, Mukherjee P, Varambally S, Manne U. Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma. Neoplasia. 2024 01; 47:100951.
Score: 0.172
-
Choi YD, Jung JY, Baek M, Khan S, Song PI, Ryu S, Koo JY, Chauhan SC, Tsin A, Choi C, Kim WJ, Kim M. APE1 Promotes Pancreatic Cancer Proliferation through GFRa1/Src/ERK Axis-Cascade Signaling in Response to GDNF. Int J Mol Sci. 2020 May 19; 21(10).
Score: 0.134
-
Sikander M, Malik S, Khan S, Kumari S, Chauhan N, Khan P, Halaweish FT, Chauhan B, Yallapu MM, Jaggi M, Chauhan SC. Novel Mechanistic Insight into the Anticancer Activity of Cucurbitacin D against Pancreatic Cancer (Cuc D Attenuates Pancreatic Cancer). Cells. 2019 Dec 31; 9(1).
Score: 0.131
-
Kumari S, Khan S, Sekhri R, Mandil H, Behrman S, Yallapu MM, Chauhan SC, Jaggi M. Protein kinase D1 regulates metabolic switch in pancreatic cancer via modulation of mTORC1. Br J Cancer. 2020 01; 122(1):121-131.
Score: 0.130
-
Chaturvedi P, Singh AP, Chakraborty S, Chauhan SC, Bafna S, Meza JL, Singh PK, Hollingsworth MA, Mehta PP, Batra SK. MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. Cancer Res. 2008 Apr 01; 68(7):2065-70.
Score: 0.058
-
Andrianifahanana M, Chauhan SC, Choudhury A, Moniaux N, Brand RE, Sasson AA, Pour PM, Batra SK. MUC4-expressing pancreatic adenocarcinomas show elevated levels of both T1 and T2 cytokines: potential pathobiologic implications. Am J Gastroenterol. 2006 Oct; 101(10):2319-29.
Score: 0.052
-
Moniaux N, Varshney GC, Chauhan SC, Copin MC, Jain M, Wittel UA, Andrianifahanana M, Aubert JP, Batra SK. Generation and characterization of anti-MUC4 monoclonal antibodies reactive with normal and cancer cells in humans. J Histochem Cytochem. 2004 Feb; 52(2):253-61.
Score: 0.011